Grannus Therapeutics

Indianapolis, IN · Founded 2020 · Privately Held (backing)

Operator of a pre-clinical stage biotechnology company intended to support a cancer treatment. Grannus Therapeutics is based in Indianapolis, IN and was founded in 2020. It was valued at $5 million at its seed round in Jan 2022, the last priced event on record. It has raised $2.9 million across 2 recorded rounds; the latest was an $800,000 debt round in Nov 2023.

PMV mark · valuation
$5.0M
Oct 2026
Priced at
its seed round
Jan 2022
Total raised
$2.9M
Last round
Debt
Nov 2023
What is Grannus Therapeutics worth?
$5.0MPrivateMarketView mark · Oct 2026

Valued at $5.0M at its seed round, Jan 2022. Nothing has traded since.

Free account
More of Grannus Therapeutics with a free account
  • ·Watch Grannus Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Grannus Therapeutics funding history

2 rounds
DateRoundRaisedPost-money
Nov 2023Debt$800K▮
Jan 2022Seed Round$950K▮
Unlock post-money valuations

Membership and data by Private Market View

Grannus Therapeutics valuation

Grannus Therapeutics was valued at $5 million at its seed round in Jan 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Grannus Therapeutics raised?

Grannus Therapeutics has raised $2.9 million in total; 2 of its rounds are on record. The largest on record was a $950,000 seed round in Jan 2022; the most recent was an $800,000 debt round in Nov 2023.

Grannus Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently in Jan 2024 ($800,000 sold to 9 investors).

How Grannus Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Grannus Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Grannus Therapeutics

What is Grannus Therapeutics worth?
Grannus Therapeutics is valued at $5.0M as of Oct 2026. Valued at $5.0M at its seed round, Jan 2022. Nothing has traded since.
How much has Grannus Therapeutics raised?
Grannus Therapeutics has raised $2.9M in total funding across 2 recorded rounds.
When did Grannus Therapeutics last raise?
Grannus Therapeutics last raised in Nov 2023 (Debt), raising $800K.